Intravenous anti-CD79b antibody–drug conjugate that delivers the microtubule inhibitor MMAE to CD79b-positive B cells.
Anti-CD79b monoclonal antibody delivers the cytotoxic payload MMAE to CD79b-positive B cells. After binding and internalization, proteolytic cleavage releases MMAE, which inhibits tubulin polymerization, causing G2/M cell-cycle arrest and apoptosis.
NO
INDIRECT
Polatuzumab vedotin binds CD79b on B cells; after internalization it releases MMAE, which binds β-tubulin (Vinca site) to inhibit microtubule polymerization, causing G2/M arrest and apoptosis in CD79b+ cells.
A personalized cancer vaccine composed of patient-specific tumor neoantigens administered subcutaneously to load antigen-presenting cells (primarily dendritic cells), enhance MHC I/II presentation, and expand tumor-specific CD8+ cytotoxic and CD4+ helper T cells to eliminate residual micrometastatic disease and establish immune memory in post-resection stage IIIA lung adenocarcinoma.
Personalized neoantigen peptide vaccine given subcutaneously to be taken up by antigen‑presenting cells (mainly dendritic cells), enhancing MHC I/II presentation and priming/expanding neoantigen‑specific CD8+ cytotoxic and CD4+ helper T cells to eradicate residual tumor cells and establish durable immune memory.
NO
INDIRECT
The vaccine primes neoantigen-specific CD8+ T cells that kill cells presenting the specific neoantigen peptide on HLA class I (e.g., HLA-A) via perforin/granzyme or Fas–FasL. HLA-A alone is not a cytotoxic target.
Antibody–drug conjugate targeting Nectin-4 that delivers the microtubule-disrupting payload MMAE to induce tumor cell death.
Nectin-4–targeted antibody–drug conjugate; the antibody binds Nectin-4 on tumor cells, is internalized, and a cleavable linker releases MMAE, which binds tubulin to inhibit microtubule polymerization, causing G2/M arrest and apoptotic cell death in Nectin-4–expressing tumors.
YES
DIRECT
The ADC binds Nectin-4 on target cells, is internalized, and releases MMAE, which inhibits tubulin polymerization, causing G2/M arrest and apoptosis.
Antibody–drug conjugate targeting Nectin-4 that delivers the microtubule-disrupting payload MMAE to induce tumor cell death.
Nectin-4–targeted antibody–drug conjugate; the antibody binds Nectin-4 on tumor cells, is internalized, and a cleavable linker releases MMAE, which binds tubulin to inhibit microtubule polymerization, causing G2/M arrest and apoptotic cell death in Nectin-4–expressing tumors.
NO
INDIRECT
The ADC binds Nectin-4 on tumor cells, is internalized, and releases MMAE, which binds beta-tubulin to disrupt microtubules and induce apoptosis; beta-tubulin expression alone does not target cells for killing.
Anti-CD20 monoclonal antibody that induces ADCC/CDC and apoptosis of CD20-positive B cells.
Chimeric anti-CD20 monoclonal antibody that binds CD20 on B cells and depletes CD20-positive lymphocytes via antibody-dependent cellular cytotoxicity, complement-dependent cytotoxicity, and direct induction of apoptosis.
YES
DIRECT
Rituximab binds CD20 on B cells and eliminates them via Fc-mediated ADCC and complement-dependent cytotoxicity; it can also trigger apoptosis upon CD20 crosslinking.